TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01874730
Drug: Volulyte® (6% HES 130/0.4 in balanced solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg.
Study: NCT03406832
Drug: Heparinized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary infusion 2ml for single time
Study: NCT04551755
Drug: Ivermectin and Doxycycline
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~2. Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes
Study: NCT01322269
Drug: HQK-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 tablets, once daily for daily 26 weeks
Study: NCT03481881
Drug: Standard of care drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.
Study: NCT03021499
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsule
Study: NCT00450242
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrophilic petrolatum, dime-sized amount, applied nightly.
Study: NCT00841204
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00411762
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00411762
Drug: PHY906
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00372762
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Equivalent dose to pre-existing furosemide will be used
Study: NCT00372762
Drug: bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg to 2mg orally once or twice daily
Study: NCT00870883
Drug: N-acetylcysteine and deferoxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
Study: NCT01227759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo containing no active ingredient
Study: NCT00820950
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream applied once or twice daily for 56 days
Study: NCT04061798
Drug: ACT guided heparinization
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the ACT is \<180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.~If the ACT is \>200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is \>200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.~If the ACT at closure is 200-250 sec., 2500 IU of protamine should be administered. If \>250 sec., 5000 IU protamine. If 180-200 sec., 1000 IU protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again.
Study: NCT04061798
Drug: 5 000 IU of heparin
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 5 000 IU of heparin is given 3-5 min before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.~If the ACT at closure is between 200 and 250 s, 2500 IU protamine should be administered. If the ACT is higher than 250 s, 5000 IU protamine should be administered. If the ACT is between 180 and 200 s, 1000 IU protamine should be administered. Five minutes after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 s. If the ACT is still more than 200 s, protamine should be administered again.
Study: NCT00048893
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First induction chemotherapy: 2700 mg/m\^2 per cycle (900 mg/m\^2 per day intravenous over 1 hour for 3 consecutive days, days 1-3).~Second induction: 600 mg/m\^2 per cycle (600 mg/m\^2 intravenous over 1 hour day 1.~Immune depleting chemotherapy: 2400 mg/m\^2 per cycle (600 mg/m\^2 per day intravenous over 1 hour for 4 consecutive days, days 1-4).
Study: NCT00048893
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2 per cycle (60 mg/m\^2 slow intravenous push day 1).
Study: NCT03249831
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally daily
Study: NCT04008030
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT04008030
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT04270552
Drug: Ismigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
Study: NCT04270552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched tablets without any active substance.
Study: NCT00523718
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 1 capsule PO bid, 12 weeks
Study: NCT02414503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04265456
Drug: Acetaminophen 1300mg
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
Study: NCT00686998
Drug: AZD2624
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Suspension
Study: NCT00686998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01494649
Drug: Test Toothpaste
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.454% stannous fluoride toothpaste
Study: NCT03540043
Drug: Administration of Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botanical Drug Phase 2 clinical study
Study: NCT03540043
Drug: Administration of PUR0110 (Thykamine) 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botanical Drug Phase 2 clinical study
Study: NCT01748448
Drug: Placebo: Oil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02815917
Drug: [18F]FTP PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: All PET/CT imaging sessions will include an injection of \[18F\]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of \[18F\]FTP in healthy volunteers and cocaine-dependent volunteers.
Study: NCT03540043
Drug: Administration of PUR0110 (Thykamine) 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botanical Drug Phase 2 clinical study
Study: NCT03540043
Drug: Administration of PUR0110 (Thykamine) 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botanical Drug Phase 2 clinical study
Study: NCT01603238
Drug: [14C]-LC15-0444
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral administration of \[14C\]-LC15-0444 50 mg, containing 4.9 MBq \[14C\]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
Study: NCT01604109
Drug: 10 % w/v CPP-ACP paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply once a day at school by school teacher, following fluoride toothbrushing after lunch
Study: NCT03640559
Drug: Seroguard
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03640559
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00099320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
Study: NCT03091400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
Study: NCT02561000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01436162
Drug: Antidepressant + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Study: NCT01257828
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg BID orally for 14 days prior to surgery and 28 days after the surgery
Study: NCT04252521
Drug: dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dexketoprofen trometamol in 100 ml normal saline solution
Study: NCT04252521
Drug: metoclopramide+dexketoprofen trometamol
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide+50 mg dexketoprofen trometamol in 100 ml normal saline solution
Study: NCT04959201
Drug: NMDAE plus AO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of an NMDA enhancer plus a drug with antioxidant property for the treatment of schizophrenia.
Study: NCT04959201
Drug: NMDAE plus Placebo Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of an NMDA enhancer plus placebo as a comparator.
Study: NCT00995540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tid subcutaneous injection for 12 weeks
Study: NCT03135548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks treatment
Study: NCT02567539
Drug: Radiosensitive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiosensitive therapy with Temozolomide
Study: NCT03463317
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
Study: NCT03997383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
Study: NCT02913261
Drug: Best Available Therapy (BAT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
Study: NCT04093219
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of IV tylenol for pain
Study: NCT01191372
Drug: placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile saline for injection
Study: NCT01191372
Drug: ARC19499
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tissue factor pathway inhibitor (TFPI) aptamer
Study: NCT00870220
Drug: Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
Study: NCT02994433
Drug: Placebo gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
Study: NCT04236141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of Placebo (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
Study: NCT00060554
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02616146
Drug: ENG-E2 125 μg/300 μg vaginal ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
Study: NCT02616146
Drug: LNG-EE 150 μg/30 μg COC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
Study: NCT01340872
Drug: ST10-021
Normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [ILIA SUPER SERUM SKIN TINT (ST10 PORTO FERRO)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg capsules to be taken orally twice a day for 12 weeks
Study: NCT01340872
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching sugar pill to be taken orally twice a day for 12 weeks
Study: NCT00257166
Drug: placebo oral capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
Study: NCT02280395
Drug: RUT058-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
Study: NCT02280395
Drug: Sterile saline for irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
Study: NCT02088112
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 IV Q2W
Study: NCT02418559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
Study: NCT04600817
Drug: TJ107 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QW8
Study: NCT03039621
Drug: Ergoferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral use.
Study: NCT03039621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral use.
Study: NCT01732094
Drug: hpHMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
Study: NCT01459029
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
Study: NCT00140543
Drug: sirolimus versus mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02616445
Drug: UE2343
Approvals — FDA: no, EMA: no, PMDA: no
Description: * UE2343~* 10mg, 20, 35mg~* twice daily for 9 days
Study: NCT02616445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 10mg, 20, 35mg~* twice daily for 9 days
Study: NCT02616445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cross-over study~* single dose administered twice (on day 1 and day 8)~* study duration 17 days
Study: NCT02616445
Drug: UE2343
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cross-over study~* UE2343~* single dose administered twice (on day 1 and day 8)~* study duration 17 days
Study: NCT02616445
Drug: UE2343
Approvals — FDA: no, EMA: no, PMDA: no
Description: * UE2343~* twice daily for 3 days~* single dose on day 4
Study: NCT04621097
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: regular medications
Study: NCT02015299
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet matching placebo/day for 26 weeks
Study: NCT01727700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04578548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules administered orally
Study: NCT03608072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sequential dose groups
Study: NCT05420350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pill matched with lamotrigine to be taken once or twice a day per study timeline Oral pill matched with bupropion to be taken twice a day
Study: NCT01842633
Drug: Paracetamol and Caffeine
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
Study: NCT01842633
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Caplets containing 200 mg of ibuprofen
Study: NCT00095875
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00971165
Drug: Chlorthalidone plus amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
Study: NCT01355484
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subject will receive placebo for the duration of the trial
Study: NCT02677298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection, 0.9% sodium chloride divided in five 0.1 mL i.m. injections into glabellar area
Study: NCT00263796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline, IV over 4 hours
Study: NCT02616601
Drug: Generic Fluorouracil Cream
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical cream, generic formulation of the brand product.
Study: NCT02616601
Drug: Carac® (Fluorouracil) Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream, brand product.
Study: NCT02616601
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream, placebo. Has no active ingredient.
Study: NCT03123185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet and solution formulation
Study: NCT03252340
Drug: ADSTEM Inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.
Study: NCT03851731
Drug: Naltrexol
Normalized name: 6-beta-naltrexol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal spray
Study: NCT01905215
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
Study: NCT04041791
Drug: Gentamicin Sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin is an aminoglycoside antibiotic.
Study: NCT01784419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
Study: NCT02280083
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03597217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01757236
Drug: CLINDAMYCIN
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01757236
Drug: FLUOROQUINOLONE
Normalized name: Fluoroquinolone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00188071
Drug: ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00188071
Drug: ketoprofen + paracetamol
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no